Effect of inhaled airway widening medication on exhaled nitric oxide (an airway inflammation marker) in chronic obstructive pulmonary disease

Not Applicable

Completed

• Conditions: chronic obstructive pulmonary disease; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12616000140459
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-02-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Diagnosis of chronic obstructive pulmonary disease, aged 45 years or older, smoking history of more than 10 pack years, taking inhaled salbutamol as required, post-bronchodilator FEV1/FVC of less than 70% and FEV1 < 80% predicted.

Exclusion Criteria

No exacerbations or use of antibiotics in the two weeks preceding study participation. No patients with diagnosed lung cancer, bronchiectasis, or other significant co-morbidity. No patients unable to perform the 50mL/s exhaled nitric oxide manoeuvres in accordance with American Thoracic Society guidelines

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in exhaled nitric oxide a was assessed by measurement of exhaled nitric oxide immediately before and 15 minutes after the dose of inhaled salbutamol. Measurements were undertaken using a chemiluminescence nitric oxide analyser according to American Thoracic Society and European Respiratory Society guidelines.[Immediately prior to and 15 min after dose of inhaled salbutamol.]

Secondary Outcome Measures

Name	Time	Method
Change in flow-independent exhaled nitric oxide parameter, JawNO (the maximal flux of nitric oxide from the airway compartment). Measurements of exhaled nitric oxide were undertaken using a chemiluminescence nitric oxide analyser at multiple expiratory flow rates. From these, JawNO was calculated.[Immediately prior to and 15 min after dose of inhaled salbutamol.];Change in flow-independent exhaled nitric oxide parameter, CANO (the distal airway/alveolar concentration of nitric oxide). Measurements of exhaled nitric oxide were undertaken using a chemiluminescence nitric oxide analyser at multiple expiratory flow rates. From these, CANO was calculated.[Immediately prior to and 15 min after dose of inhaled salbutamol.]